The Motley Fool

Is It Time To Buy Angle plc & Advanced Medical Solutions Group plc?

Shares in ANGLE (LSE: AGL) jumped by as much as 6.4% during early trade this morning, after the company reported that it had secured the first commercial sales of the group’s Parsortix system.

Big market, slow growth

The Parsortix system is the specialist MedTech company’s flagship product that uses patented micro-fluidic technology to capture and harvest circulating tumour cells from blood. Angle believes that the addressable market for this kind of product could be worth as much as £250m, although the company didn’t reveal any details about the customers or the revenue derived from the initial sales reported today. Angle expects revenue from the medical research tool to be initially modest as it grows over time.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

City analysts believe that the Parsortix system could generate sales of £340,000 for the year to 30 April 2016, which works out at around four-to-five months of sales. Next year, sales are expected to pick up and analysts are predicting Angle will generate revenues of £2.2m for the full-year. However, even though sales of Angle’s Parsortix system are set to take off over the next 12-to-24 months, analysts expect profit to remain elusive for the time being. 

So for now Angle remains a speculative play. Until the company is able to show that it can generate a consistent profit, its shares aren’t suitable for risk-averse investors. 

Another strong performance

In what’s become something of a regular occurrence for Advanced Medical Solutions (LSE: AMS), the company issued another upbeat trading update today, reporting that it was on track to meet the market’s expectations for revenue and profitability for full-year 2015.

What’s more, Advanced Medical said today that the regulatory approvals received this year for its new antimicrobial foams, together with the clearance to market its sutures in the US, are expected to contribute to growth in 2016.

Commenting on today’s trading update, Chris Meredith, CEO of AMS, said:

“The Group continues to deliver strong organic growth supported by a pipeline of new products coming out of our Research and Development teams. We are confident that AMS is very well positioned to deliver further growth.”

If you’re looking for an investment to revolutionise your portfolio’s returns, Advanced Medical could be an excellent choice. The company has consistently outperformed since 2009. Net profit has grown at a compound annual rate (CAGR) of 36% since 2009, and reported earnings per share have expanded at a CAGR of 27.7%. Over the same period, the company’s shares have gained 450%, outperforming every major stock index by several hundred percentage points. 

That said, Advanced Medical’s shares don’t come cheap. They’re currently trading at a forward P/E of 26.9, falling to 25.3 for 2016 and support a dividend yield of 0.4%. Still, sometimes it’s worth paying extra for quality. 

The bottom line

Based on my analysis, Advanced Medical looks attractive after today’s update, but risk-adverse investors should avoid Angle. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.